Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Implications de la déclaration sur l’accord sur les ADPIC et la santé publique adoptée a Doha - Série "Economie de la santé et médicaments", No. 012
(2002; 73 pages) [English] [Spanish] View the PDF document
Table of Contents
View the documentAvant-propos
View the documentRemerciements
View the documentSigles et acronymes
View the documentRésumé d’orientation
View the documentIntroduction
View the documentPortée
View the documentLe rôle des ADPIC et des DPI
Open this folder and view contentsMesures concernant la santé publique
Open this folder and view contentsFlexibilité des ADPIC
Open this folder and view contentsMembres ayant des capacités de fabrication insuffisantes ou n’en disposant pas
View the documentTransfert de technologie aux PMA
View the documentProrogation de la période de transition pour les PMA
View the documentTraitement spécial selon l’Accord sur les ADPIC
View the documentStatut juridique de la Déclaration sur l’Accord sur les ADPIC et la santé publique
View the documentProblèmes non couverts dans la Déclaration
View the documentConclusions
View the documentAnnexe 1 - Déclaration sur l’Accord sur les ADPIC et la santé publique adoptée à Doha
View the documentAnnexe 2 - Niveaux de développement de l’industrie pharmaceutique, par pays
View the documentRéférences


1. Abbott F. The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO. Journal of International Economic Law, Oxford University Press, 2002.

2. Abbott F. Compulsory Licensing for Public Health Needs. The TRIPS Agenda at the WTO after the Doha Declaration on Public Health. Document occasionnel 9. Genève, Quaker United Nations Office, 2002.

3. Attaran A. The Doha Declaration on the TRIPS Agreement and Public Health: Options for TRIPS Council. Paragraphe 6. Projet de travail, 2002.

4. Ballance R, Pogány J, Forstner H. The World’s Pharmaceutical Industry. An International Perspective on Innovation, Competition and Policy. Vienne, Organisation des Nations Unies pour le développement industriel, 1992.

5. Bond P. Globalization, Pharmaceutical Pricing and South African Health Policy: Managing Confrontation with U.S. Firms and Politicians. International Journal of Health Services, 23 mars 1999.

6. Chirambo M. The International Patent System. Regional Approaches. Communication à la Conférence de l’OMPI sur le système international des brevets. Genève, 25-27 mars 2002.

7. CNUCED. The TRIPS Agreement and Developing Countries. Genève, Conférence des nations unies sur le Commerce et le Développement, 1996.

8. Commission européenne (DG1). Note for the Attention of the 113 Committee (Deputies), 5 octobre 1998. Objet: WTO TRIPS/World Health Organization - Revised Drug Strategy. Réunion du groupe de travail ad hoc, 13-16 octobre 1998.

9. Commission européenne Déclaration ministérielle de l’OMC sur les accords ADPIC et la santé publique. Bruxelles, Commission européenne, 19 novembre 2001.

10. Commission européenne Tiered Pricing for Medicines Exported to Developing Countries, Measures to Prevent their Re-importation into the EC Market and Tariffs in Developing Countries. Document de travail. Bruxelles, Commission européenne (DG Commerce), 22 avril 2002.

11. Correa C. Intellectual Property Rights, the WTO and Developing Countries. The TRIPS Agreement and Policy Options. Londres et New York, Zed Books, 2000.

12. Correa C. Implementing National Public Health Policies in the Framework of the WTO Agreements. Journal of World Trade, vol. 34, no. 5, 2000.

13. Correa C. Integrating Public Health Concerns into Patent Legislation in Developing Countries. Genève, South Centre, 2000, p. 22.

14. Correa C. Protection of Data Submitted for the Regulation of Pharmaceuticals. Implementing the Standards of the TRIPS Agreement. Genève, South Centre, 2002.

15. Correa C. Trends in Drug Patenting. Case Studies. Buenos Aires, Corregidor, 2001.

16. Drahos P. Developing Countries and International Intellectual Property Standard-Setting. Etude rédigée pour la Commission du Royaume-Uni sur les droits de propriété intellectuelle, 2002. Disponible à l’URL: http://www.iprcommission.org

17. Engelberg A. Implementing the Doha Declaration. A Potential Strategy for Dealing with Legal and Economic Barriers to Affordable Medicines, 2002. Disponible à l’URL: http://www.cptech.org/ip/health/pc/engelberg.html

18. Gillespie-White L. What Did Doha Accomplish? 2001. Disponible à l’URL: http://mail.iipi.org/db/views/detail.asp?itemID=21

19. Harmon A, Pear R. Canada Overrides Patent for Cipro to Treat Anthrax. New York Times, 19 octobre 2001.

20. Institut international de propriété intellectuelle. Patent Protection and Access to HIV/AIDS Pharmaceuticals in Sub-Saharan Africa. Washington D.C., Institut international de propriété intellectuelle, 2000.

21. Jackson J. The Jurisprudence of GATT and the WTO. Cambridge, Cambridge University Press, 2000.

22. Kettler H. Using Intellectual Property Rights Regime to Meet Global Health Needs. Commission sur les droits de propriété intellectuelle, 2002. Disponible à l’URL: http://www.ciprcommission.uk

23. MSF Fatal Imbalance. The Crisis in Research and Development for Drugs for Neglected Diseases Genève, Médecins Sans Frontières, 2001.

24. OMS. Global Comparative Pharmaceutical Expenditures with Related Reference Information. Health Economics and Drugs, EDM Series No 3. Genève, Organisation mondiale de la Santé, 2000. EDM/PAR/2000.2.

25. OMS. Globalization, Patents and Drugs. An Annotated Bibliography, 2nd ed. Health Economics and Drugs, EDM Series No 10. Genève, Organisation mondiale de la Santé, 2001. EDM/PAR/2001.1.

26. OXFAM. TRIPS and Public Health. The Next Battle. Londres, OXFAM, 2002.

27. Raja K. Health Declaration Gives Green Light to Put Public Health First. Third World Economics. Trends and Analysis, vol 268, no.1, 2001.

28. Reichman J. From Free Riders to Fair Followers: Global Competition Under the TRIPS Agreement. New York University Journal of International Law and Politics, vol.29, no.1-2, 1997.

29. Reichman J. Patents and Public Health in Developing Countries: Bargaining Around the TRIPS Impasse. Communication à la Conférence sur l’accès aux médicaments essentiels, University of Wisconsin School of Law, 8-10 mars 2002.

30. South Centre. AIDS and Anthrax: Strange Bedfellows? South Letter, vol. 3-4, 2001.

31. ‘t Hoen E. The Declaration on TRIPS and Public Health: A Step in the Right Direction. Bridges, année 5, no. 9, 2001.

32. ‘t Hoen E. TRIPS, Pharmaceutical Patents and Access to Essential Medicines: A Long Way from Seattle to Doha. Chicago Journal of International Law, vol. 3, no. 1, printemps 2002.

33. Thorpe P. Study on the Implementation of the TRIPS Agreement by Developing Countries. Etude rédigée pour la Commission du Royaume-Uni sur les droits de propriété intellectuelle (à venir 2002).

34. Vandoren P. Clarification of the Relationship between TRIPS and Public Health Resulting from the WTO DOHA Ministerial Declaration. The Journal of World Intellectual Property, vol. 5, no. 1, janvier 2002.

35. Velasquez G, Boulet P. Mondialisation et accès aux médicaments: Perspectives sur l’accord ADPIC de l’OMC (version révisée). Genève, Organisation mondiale de la Santé, 1999. WHO/DAP/98.9.

36. VSO. Street Price. Making Medicines Affordable for Poor Countries. Londres, VSO, 2001.

37. Weisbrot M. Rich-Country Protectionism Puts WTO on the Slow Track. Third World Economics. Trends and Analysis, vol. 268, no.1, 2001.

to previous section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017